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Attention Deficit Hyperactivity Disorder (ADHD) holds the distinction of
being both the most extensively studied pediatric mental disorder and one of
1
the most controversial. This is partly due to the fact that it is also the most
2
commonly diagnosed mental disorder among minors. On average, one in every ten to 15 children in the U.S. has been diagnosed with the disorder and
one in every 20 to 25 uses a stimulant medication—often Ritalin, Adderall,
3,4
or Concerta—as treatment. The biggest increase in youth diagnosed with
ADHD and prescribed a stimulant drug occurred during the 1990s, when the
prevalence of physician visits for stimulant pharmacotherapy increased
5-8
five-fold. This unprecedented increase in U.S. children using psychotropic
9
medication triggered an intense public debate.
This overview is drawn from our new book, Medicating Children: ADHD and Pediatric Mental Health, published by Harvard University Press, 2009.

Learning objectives (LO) for this issue:
1. Assess the clinical, educational and economic factors that influence the treatment of ADHD.
2. Evaluate the debate over the overuse of medications in children.
3. Describe the ambiguities in classification and diagnosis of ADHD.
This CME activity is intended for child and adult psychiatrists, pediatricians and other health care professionals with an interest in the psychopharmacology and treatment practices for child and adolescent psychiatric disorders.
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Ironically, neither the debate nor
ADHD and stimulants were new.
Methylphenidate, more commonly
known by the trade name Ritalin, was
first introduced in the United States in
1955, and approved by the Food and
Drug Administration in 1961 for use in
children with severe behavioral problems.10 Prior to Ritalin, another stimulant (benzedrine) had been tested and
used by small numbers of children as
early as 1937.11 As for ADHD, the basic
symptoms of the disorder have gone by
several different diagnostic labels since
the early 1930s: “organic drivenness,”
“minimal brain damage,” “hyperkinetic
impulse disorder,” “minimal brain dysfunction,” “hyperkinesis,” “hyperactive
child syndrome,” and “attention deficit
disorder.”12 Even the core of the controversy, children using physician-prescribed psychoactive drugs, dates back
almost four decades. Nevertheless, negative publicity over the “drugging of
problematic children” in the early
1970s—together with another negative media blitz and a wave of lawsuits
against physicians, school personnel
and the American Psychiatric Association in the late 1980s—greatly reduced
the prevalence of ADHD diagnoses and
pharmacotherapy compared with current levels. When the 1990s began,
most schools across the country had
only a handful of (if any) children diagnosed with ADHD and using stimulants.13 By 2000, most every classroom
in the United States had, on average, at
least one to two such students treated
for the disorder.4,14,15 Currently, almost
8% of youth aged 4 to 17 years have a
diagnosis of ADHD, and approximately
4.5% have the diagnosis and are taking
medication for the disorder.16,17
The massive increase in the number
of U.S. children diagnosed with ADHD
and using stimulants stemmed primarily from a confluence of trends (clinical, economic, educational, political),
an alignment of incentives (among clinicians, educators, policy makers,
health insurers, the pharmaceutical industry), and the sizeable growth in scientific knowledge about ADHD and
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stimulants that converged in the first
half of the 1990s. Growing political
movements advocating for children’s
welfare and mental health consumers,18-24 along with the decreasing stigma
associated with mental disorders, led to
three seemingly minor policy changes
in the early 1990s—to a federal income
support program (Supplemental Security Income, SSI), a federal special education program (Individuals with Disabilities Education Act, IDEA), and a
joint federal-state public health insurance
program
(Medicaid)—that
helped trigger the surge in ADHD diagnoses and related stimulant use.25,26
ADHD and stimulant use have been
and remain controversial, in part because most children are diagnosed and
medicated as the result of decisions
made by their parents and clinicians. In
short, the treatment is ordinarily decided for them instead of by them, a scenario that invites criticism that a patient’s autonomy is being compromised
to some extent.27,28,29 Yet many medical
decisions involving children are made
this way and are not controversial.
Mental disorders such as ADHD, however, are different. They are regularly
diagnosed based mainly, if not solely, on
the presence of behavioral symptoms—inattentiveness, hyperactivity,
and impulsiveness—that are common—this despite the fact that the
DSM-IV outlines a far more extensive
and rigorous approach to making a
proper diagnosis of ADHD than relying
exclusively on rating an individual’s
symptoms. The key difference is one of
degree. Children with ADHD are significantly more inattentive, impulsive,
distractible, and/or fidgety than their
peers, such that their symptoms cause
major personal impairment and interfere with daily human functioning. 30
At the same time, mental disorders
usually involve matters of degree, so
why has ADHD been more controversial than other mental disorders? One of
the main reasons has to due with the
disorder’s dominant educational aspect.
The majority of ADHD diagnoses originate with the observations of a child’s

31

teacher, and many of the disorder’s
symptoms—rated
on
behavioral
scales—require teacher reports to make
a diagnosis. The child
“often fails to give close attention
to details or makes careless mistakes in schoolwork, work, or
other activities,”
“often does not follow through
on instructions and fails to finish
schoolwork, chores, or duties in
the workplace,”
“often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort
[such as school work or homework],”
“often leaves seat in classroom
or in other situations in which remaining seated is expected,”
“often blurts out answers before
questions have been completed”).”32-35
With ADHD, teachers are typically the
primary source of diagnostic information.36 Only a minority of children with
the disorder exhibit symptoms during a
37,38
physician’s office visit.
Similar to all mental disorders, however, there is no definitive medical test
(blood, urine, radiological) to verify an
ADHD diagnosis. Therefore, the diagnosis contains a large element of unavoidable subjectivity, which leaves it
open to competing definitions of what
is considered “normal” childhood behavior.39 The United States, for example, consumes the majority of the
world’s production of stimulants with
school-age children using as much as
three times more psychiatric medication than children in the rest of the
world combined.40,41 In some European
countries, only a child psychiatrist can
prescribe a stimulant for a minor diagnosed with ADHD, while in other
countries the drugs can only be prescribed if approved by three independent professionals.42 These regulations
have precluded a similar growth in
stimulant use in other developed countries, despite the fact that international

studies suggest that the prevalence of
ADHD is similar across different Western countries when clinicians use
roughly the same diagnostic procedures.43,44
For these and other reasons, people
debate whether the ADHD and stimulant phenomenon in the U.S. is more
the story of medical science making
progress on a long misunderstood disorder or if ADHD has largely been “socially constructed,” under the biological
vision of mental health, as a response to
non-medical problems such as under-performing schools, increased academic demands and expectations, and
higher poverty and divorce rates than
existed before the 1970s.46 What makes
this question so contentious is that the
debate is political and philosophical in
nature because ADHD and stimulants
do not exist in a clinical vacuum.47,48 All
mental disorders and mental health
care, notes medical anthropologist Byron Good, are “social, psychological and
cultural to the core,” powerfully influenced by public opinion and varying expectations of what is considered normal
and abnormal behavior by girls and boys
of very different ages and stages of development.49 Meanwhile, teachers, parents,
clinicians, health plans, and policy-makers are all trying to determine—within their separate but overlapping spheres of influence—what is in
the best interests of literally millions of
children.

The Core of the Controversy
over ADHD and Stimulants
It seems virtually impossible to give a
presentation on or even just talk about
ADHD and stimulants without being
asked if the drugs are overused in the
United States. We assume that many
readers of this paper will have the same
curiosity. The answer is “yes” and “no.”
In some geographic areas and among
specific childhood populations, ADHD
appears to be over-diagnosed and the
drugs overused. However, several of the
same research findings that identify this
overuse also identify areas and popula-
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tions in which ADHD is very likely
underdiagnosed and the drugs
underused with serious personal and
public health consequences.50-54
This more complicated and nuanced
reality of both over- and under-use of
stimulants is rarely presented in the
popular press, but it reflects two key factors. First, while a valid (real, genuine)
disorder, ADHD is also—similar to
many mental disorders—one that primary care physicians often diagnose in
a less than strictly thorough manner
due to the intense economic and time
constraints they face, as well as to their
training (or lack thereof) in the area of
mental disorders.55,56,57 This reality is important, because primary care physicians make the majority of ADHD diagnoses and stimulant drug prescrip58,59
tions. In addition, it is not clear to
clinicians, researchers or the general
public if ADHD is primarily a medical
disorder, a behavioral problem manifesting primarily in schools, a mental
illness, or an evolutionary disorder of
human adaptation.60,61 It is also not
self-evident how hyper, inattentive,
and/or impulsive a child has to be to
warrant a diagnosis, because the benchmark of comparison for diagnosing a
child is whatever is considered “normal” for his or her peer age-group.
The ambiguity over ADHD’s classification, and the manner in which it is
regularly diagnosed, contributes to significant variation in diagnostic and
treatment styles by clinicians: prevalence rates for the disorder range from
as low as 2% to as high as 18% in different communities across the United
States.62,63 This variation results in a serious mismatch between the need for
and provision of pharmacotherapy,
with both “under-treatment” of
ADHD64 and the “over-use” of stimulants by many children who do not
meet full ADHD diagnostic criteria (as
well as some children who exhibit no
53
symptoms of ADHD at all).
The second factor that fuels the debate is that stimulants are heavily regulated Schedule II drugs, which are effective in helping individuals with or

65,66

without ADHD.
In other words,
they enhance most individuals’ ability
to sustain their level of concentration.67,68 This is not the way the public
understands medical interventions to
operate. The general view of medicines
is that they treat people with a chronic
or acute episode of illness or a disorder,
but that they would either have no effect or possibly be harmful to someone
who did not have an illness or a disorder. Consequently, when stimulants
help those with ADHD and enhance
the performance of individuals without
the disorder, they often invite skepticism about the appropriateness of stimulant use by millions of children. 68
Even as scientific understanding of
ADHD advances, it is hard to imagine
the social and political controversy
over ADHD abating. As a diagnosis
and form of treatment, ADHD and
stimulant pharmacotherapy illustrate
both the success that science is capable
of producing—when applied to the
study of mental disorders—and its limitations. Researchers have made tremendous progress over the last three
decades in increasing our understanding of ADHD, but when it comes to diagnosing most mental disorders our system is still far behind other branches of
medicine, notes E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University. “On an individual level, for many parents and families, the experience can be a disaster; we
must say that.” For these families, the
search for a diagnosis is best seen as a
process of trial and error that may not
end with a definitive answer. If a family
can find some combination of treatments that help a child improve,
Costello adds, “then the diagnosis may
not matter much at all.”69 ADHD is
more straightforward and easier to diagnosis in children than, for example, bipolar disorder or autism. Yet, as previously noted, diagnosing ADHD still relies on some combination of interviews
with children (who often do not exhibit symptoms in a clinician’s office or
are reluctant or unable to talk about
themselves the way an adult would),

behavioral checklists, less-than-precise
rating scales (that measure the existence and severity of ADHD symptoms
along the lines of “never,” “occasionally,” “often,” “very often”), and reports
from teachers and parents.

Clinical Uncertainty and
Boundary Drawing
Ultimately, then, diagnosing and treating ADHD is still partially an art, despite the fact that the science applied to
it has improved dramatically in recent
decades. At the heart of the controversy over ADHD were questions of
boundary drawing. Children exhibit
symptoms of inattentiveness, hyperactivity, and impulsiveness along a continuum. Despite the fact that scientific
research can inform our choices, where
the boundary between ADHD and typical childhood behavior is located is ultimately a political and social choice,
not a scientific one. No amount of clinical research, therefore, can resolve this
question for us. Moreover, to the extent
that the boundary between sickness
and health is, in the case of mental disorders such as ADHD, demarcated
without the ability to reference objective clinical signs or indicators of illness, debates about underdiagnosis or
overdiagnosis invariably tap into society’s ambivalence about mental disorders. The DSM was designed to identify
children with the severest symptoms,
those with the lowest levels of functional ability. Yet the DSM is not applied in a vacuum: Social, political, and
economic forces impinge on where
physicians, educators, program administrators, and others decide to locate the
boundaries of medical dysfunction.
Criticisms of ADHD are criticisms both
of the limits of clinical knowledge and
of the extra-clinical forces that
influence diagnostic decision-making.
ADHD, of course, is not alone; the diagnoses of all mental disorders are subject
to influences outside of clinical medicine.
ADHD, however, is unique in the extent
to which it elicits intense reactions from
people. Because the symptoms of ADHD
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are often most evident in the school setting, where adults make sometimes tremendous demands on children, some
critics worry that the identification of
children with the disorder is driven more
by the wants and expectations of teachers,
parents, and school administrators than by
the needs of the students. More important,
because ADHD can be treated with pharmaceutical medication produced by major
companies, other critics worry (for good
reason) about the influence of corporate
profit-seeking motives on the diagnosis of
children. ADHD is among the most visible and controversial mental disorders, in
short because it is a vehicle through which
many controversial social and political
trends can be criticized.
In the middle of this confusion are the
parents of children with ADHD. They
must decide whether to accept the label
of the disorder, and they must choose
which of the many forms of treatment
and school-based interventions to pursue: behavioral therapy alone, medication alone, medication in combination
with behavioral therapy, which medication, which kinds of behavioral therapy.
The path to choose is far from evident,
and choices are constrained by
healthcare financing arrangements and
the attitudes of teachers and physicians
toward their children’s ADHD. In addition, critics like Peter Breggin and Phyllis
Schlafly write for a broad audience with
colorful anecdotes and pithy phrases, and
they publish their work in places that are
easily accessible to the general public.
Meanwhile, most researchers write for an
expert audience in specialized journals
and in language filled with clinical and
scientific jargon that lay readers might
find difficult to comprehend. As a result,
even with the advances in our understanding of the nature of ADHD and especially in our knowledge of effective
treatments brought about by extensive
research (including the Multimodal
Treatment Study of Children with
ADHD and numerous carefully designed
medication trials), parents often have
easier access to the vocal, and sometimes
extreme, views of critics of stimulant
treatment via the Internet and news re-

ports than to the research published in
scientific journals. It is little surprise,
then, that despite the growth of scientific
knowledge of ADHD and stimulants,
parents are swayed by the extremists and
unsure about which treatment to pursue;
the misinformation that fills the public
debate over ADHD only serves to
heighten parents’ fear that they will
choose the wrong path. Thus, even if par-

ents decide to medicate their child, it is a
decision that can be fraught with guilt
and anxiety. Although other mental disorders are difficult to diagnose with accuracy, although rates of childhood depression and other disorders are also on the
rise, and although the growing pediatric
use of psychotropic drugs is not limited to
stimulants, no other disorder touches
upon so many vexing social and political

questions, a situation that amplifies the
ambivalence that parents feel about medicating their children.
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tion, not all smokers successfully quit
smoking by using bupropion. It means
other factors such as genetic predisposition could contribute to the therapeutic
outcome.
Objectives: The aim of this study is to
elucidate the question of whether abstinence rates in a bupropion trial would be
different depending on genotypes.

Bupropion SR and Individual
Counseling
Efficacy of bupropion SR and individual
counseling as smoking cessation treatments was assessed in a randomized, placebo-controlled clinical trial among
adult daily smokers. Intent-to-treat analyses indicated that bupropion SR increased abstinence rates at the end of
treatment. Bupropion SR treatment also
improved latency to lapse and relapse in
survival analyses. Counseling was not associated with increases in the likelihood
of abstinence at any time point.

Six candidate genes, thought to be involved in the interaction of nicotine and
bupropion (for example, the dopamine receptor type 2, dopamine transporter,
norepinephrine transporter, serotonin
transporter, catecholamine-O-methyltrasferase) and the clinical outcomes of
smoking behavior were investigated. The
participants were 225 male smokers to
whom 150mg of bupropion SR was administered for 4 weeks.
Main Results: (1) the frequencies of
A1/A2 genotype of the dopamine receptor
type 2 TaqI A gene and the SLC6A3-9 genotype of the dopamine transporter1 gene

McCarthy et al, A randomized controlled
clinical trial of bupropion SR and individual
smoking cessation counseling. Nicotine Tob
Res. 2008 Apr;10(4):717-29.

Effect of Genetic Polymorphisms
Even though bupropion is a first line
pharmacological agent for smoking cessa-

were higher in he non-abstinence group
than in the abstinence group. The frequencies of COMTH/COMTH and
A/G genotypes of the norepinephrine
transporter gene were higher in the abstinence group than in non-abstinence
group. (2) Participants having specific
genotypes such as homozygotes (A1/A1
or A2/A2) of DRD2 TaqI A,
COMTH/COMTH, AG of NET-8 and
LL of 5-HTTLPR showed higher abstinence rate than other participants.
Conclusions: It can be concluded
that genetic diversity might determine
the effects of bupropion on smoking
cessation.
Han DH et al, Effect of genetic
polymorphisms on smoking cessation:
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